MannKind Corp. achieved noteworthy progress for international sales of its inhalable insulin Afrezza, reception of its second milestone payment from United Therapeutics for $12.5 million; and the completion of a “high potency” manufacturing facility in Danbury, Conn...

Subscribe to get the full story.


Are you a subscriber? Sign In